INTRODUCTION AND OBJECTIVES:
Micropapillary urothelial carcinoma is a rare and aggressive histologic variant of bladder cancer. Treatment guidelines recommend forgoing bacillus Calmette-Guerin (BCG) therapy in favor of early radical cystectomy for non-muscle invasive micropapillary bladder cancer (NMI-MPBC) due to high rates of disease progression. We hypothesize that management of NMI-MPBC will vary across centers.
METHODS: Patients with MPBC were identified from the National Cancer Database (2003 Database ( -2013 . Treatment trends and rates of pathological upstaging were identified. Bivariate and multivariate analyses were performed to assess differences in outcomes by treatment approach.
RESULTS: 777 patients were diagnosed with MPBC during the study period with 270 identified to have non-muscle invasive disease on presentation. BCG therapy was administered as initial therapy in 25.1% of NMI-MPBC patients and in 14.3% of non-micropapillary UC patients (p<0.001). Cystectomy was performed as primary therapy for NMI disease in 19.6% of MPBC and in 2.3% of non-micropapillary patients (p<0.001). Of the patients who underwent primary cystectomy, upstaging from NMI disease to T2-T4 disease was seen in 33.3% of the MPBC patients compared to 11.1% in patients with non-micropapillary disease (p<0.001). Upstaging to pathologic N1-3 disease was observed in 33.3% of MPBC patients compared to 11.1% non-micropapillary patients (p<0.001). Cystectomy as primary therapy for NMI-MPBC was more likely to be performed at academic (29.6%) compared to community cancer centers (11.3%) (p<0.001). On Cox regression analysis, adjusting for patient age, sex, race, comorbidities, and disease stage, care at academic cancer centers was associated with increased odds of having cystectomy as primary therapy compared to community cancer centers (OR ¼ 3.11, 95% CI 1.53-6.29).Primary BCG therapy was not utilized any more frequently between academic (26.2%) and community cancer centers (23.7%) (p¼0.64).
CONCLUSIONS: The micropapillary variant of urothelial carcinoma is associated with increased odds of disease upstaging and node-positive disease. BCG is overutilized as primary treatment in this population. NMI-MPBC patients treated at academic centers were more likely to receive radical surgery as primary treatment compared to patients at community cancer centers.
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INTRODUCTION AND OBJECTIVES: For most patients with pT1 and Carcinoma in situ (CIS) urothelial carcinoma of the bladder (UCB), intravesical induction Bacillus Calmette Gu erin (IND-BCG) is considered the gold standard treatment. However the criteria to abandon BCG therapy (i.e. BCG failure) in cases of recurrent but nonprogressive UC can be vague. In this study we aim to assess a large cohort of CIS and pT1 UCB patients treated with intravesical IND-BCG and report on the outcomes according to the grade and stage of recurrences following IND-BCG.
METHODS: The data is from a single academic institution which is the only referral site for all BCG therapies for a large metropolitan area. Patients with initial diagnosis of pT1 and CIS received induction course of intravesical BCG. Post induction cystoscopy was carried out for all patients, and follow up was three monthly for the first two years, and at least biannually thereafter.
RESULTS: From 2001 to 2014, 261 patients received IND-BCG for pT1/CIS. Post BCG status were as follows: 132 (51%) pT0, 48 (18%) CIS, 31 (12%) pT1, 32 (12%) pTaHG and 10 (4%) pTaLG. Of the patients who were pT0 post-BCG, 74% remained disease free at a median of 8 mo. 19% developed high-grade recurrences including 4% with muscle invasive UC (MIUC) at a median of 16 mo (12-27) from diagnosis. Of patients with residual CIS, 60% responded to further BCG, with progression to invasive disease in 13%. Of residual pTaHG patients, 53% became pT0 and 9% eventually had cystectomy at 32.4 mo for disease progression to CIS or ¼pT1. 10 patients had pTa-LG recurrence and one required cystectomy. Only 36% of residual pT1 patients became pT0 with 29% developing invasive disease. 39% of pT1 compared to 17% of the CIS required cystectomy at a median of 17.5 mo (p¼0.036). pT0 rates were significantly higher for CIS patients compared to pT1 (60% vs. 36%, 0.047), but similar between CIS and pTaHG. Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 THE JOURNAL OF UROLOGY â e173
